Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks ...

Merck has not shied away from splashy takeovers in the past. In 2015, the company agreed to buy U.S. lab equipment supplier ...

Stamford-based SpringWorks Therapeutics, a commercial-stage biotech company developing treatments for rare diseases and ...

Merck, in a statement, said its negotiations to buy SpringWorks are ongoing, confirming an earlier report from Reuters. The Darmstadt, Germany-based ... the approval of a product that treats ...

Stamford, Connecticut-based SpringWorks' Gomekli (mirdametinib) has become the first medicine approved for both adults and ...

Merck said in a brief statement that discussions are "advanced" but noted that "critical conditions have yet to be met" ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Merck, in a statement, said its negotiations to buy SpringWorks are ongoing, confirming an earlier report from Reuters. The Darmstadt, Germany-based company said ... The company is expecting the ...

Reacting to press reports, Germany’s Merck KGaA has confirmed it is in advanced discussions with SpringWorks Therapeutics with the aim of acquiring the US biotechnology company.

BioMed X, a German independent research institute, announces the successful completion of its oncology research project in ...